EUVIMEDEUVIMED entdecken
Klinische Studie

Clinical Trial for Safety of Porcine Islet Xenotransplantation From PERV‐C Free DPF Donor Piglets in Patients With Type 1 Diabetes

Xiaoqian Ma iD, Zhaohui Mo, Yicong Chen, Shengwang Zhang, Qi Liang, Juan Zhang, Qiong Dong, Cejun Yang, Min Yang, Min-Hua Luo, Pengfei Rong iD, Jie Cui iD und 1 weitere

Xenotransplantation · 2026-05 · 33 (3)

DOI: 10.1111/xen.70148 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Xenotransplantation, online erschienen am 17.06.2026. Verfasst von Xiaoqian Ma und 12 weiteren Autor:innen. Beteiligte Einrichtung: The Institute for Cell Transplantation and Gene Therapy, The Third Xiangya Hospital of Central South University, Changsha, China. Hauptthemen laut MEDLINE: Islets of Langerhans Transplantation, Transplantation, Heterologous, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Major Project of the Ministry of Science and Technology of Hunan Province, Natural Science Foundation of Hunan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Xenotransplantation of porcine cells, tissues or organs offers a promising strategy to address the critical shortage of human donor organs. However, cross‐species pathogen transmission, instant blood‐mediated inflammatory reaction (IBMIR)‐related liver injury, chronic over‐immunosuppression, and long‐term safety remain major challenges in porcine islet xenotransplantation. In this study, we performed a clinical trial aimed to evaluate the biosafety of neonatal porcine islet xenotransplantation in patients with type 1 diabetes.

Methods

Ten recipients were assigned to two groups receiving non‐encapsulated neonatal islet cell clusters via the jugular‐hepatic‐portal vein at mean doses of 6354 ± 835 IEQ/kg and 11 600 ± 1100 IEQ/kg, respectively. Donor pigs originated from a highly inbred, PERV‐C‐negative colony reared in designated pathogen‐free (DPF) conditions, with rigorous pathogen and PERV screening. Immunosuppression included mycophenolate mofetil, tacrolimus, belatacept, and autologous regulatory T‐cell therapy, combined with tocilizumab. Continuous low‐dose heparin was infused via a portal vein catheter was used for 7 days as anticoagulation therapy. Recipients and spouses were monitored for over 5 years, with 7 followed for more than 10 years.

Results

No PERV transmission or transplant‐related infections were detected in any recipient or contact during long‐term follow‐up. The procedure was safe and well‐tolerated, with only transient liver function and coagulation changes and mild adverse events. Both groups showed reduced exogenous insulin requirements and markedly lower hypoglycemia incidence, with better glucose control in the higher‐dose group.

Conclusion

This study demonstrates that DPF PERV‐C‐free neonatal porcine islet xenotransplantation is biologically safe and partially effective, supporting its value as a reliable donor source and foundational platform for advancing clinical islet xenotransplantation. Trial Registration ClinicalTrials.gov identifier: NCT03162237

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Islets of Langerhans TransplantationTransplantation, HeterologousDiabetes Mellitus, Type 1AnimalsHumansSwineFemaleMaleAdultImmunosuppressive AgentsHeterografts

Substanzen

Immunosuppressive Agents

Autor:innen und Institutionen

  • The Institute for Cell Transplantation and Gene Therapy, The Third Xiangya Hospital of Central South University, Changsha, China.
  • Engineering and Technology Research Center for Xenotransplantation of Human Province, Changsha, China.
  • National Health Commission Key Laboratory of Translational Research on Transplantation Medicine, Changsha, Hunan, China.
  • Department of Endocrinology, The Third Xiangya Hospital of Central South University, Changsha, China.
  • Shanghai Sci-Tech Inno Center for Infection & Immunity, National Medical Center for Infectious Diseases, Huashan Hospital, Institute of Infection and Health, Fudan University, Shanghai, China.
  • State Key Laboratory of Virology, Chinese Academy of Sciences Center For Excellence in Brain Science and Intelligence Technology, Wuhan Institute of Virology, Wuhan, China.

ORCID-Profile: Xiaoqian Ma, Pengfei Rong, Jie Cui, Wei Wang

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Major Project of the Ministry of Science and Technology of Hunan Province
  • Natural Science Foundation of Hunan Province
  • Key Project of the Science and Technology Program of Hunan Province

Zitieren

APA

Ma, X., Mo, Z., Chen, Y., Zhang, S., Liang, Q., Zhang, J., Dong, Q., Yang, C., Yang, M., Luo, M. H., Rong, P., Cui, J., & Wang, W. (2026). Clinical Trial for Safety of Porcine Islet Xenotransplantation From PERV‐C Free DPF Donor Piglets in Patients With Type 1 Diabetes. Xenotransplantation, 33(3). https://doi.org/10.1111/xen.70148

Vancouver

Ma X, Mo Z, Chen Y, Zhang S, Liang Q, Zhang J, et al. Clinical Trial for Safety of Porcine Islet Xenotransplantation From PERV‐C Free DPF Donor Piglets in Patients With Type 1 Diabetes. Xenotransplantation. 2026;33(3). doi:10.1111/xen.70148

BibTeX
@article{Ma2026,
  author = {Ma, Xiaoqian and Mo, Zhaohui and Chen, Yicong and Zhang, Shengwang and Liang, Qi and Zhang, Juan and Dong, Qiong and Yang, Cejun and Yang, Min and Luo, Min-Hua and Rong, Pengfei and Cui, Jie and Wang, Wei},
  title = {Clinical Trial for Safety of Porcine Islet Xenotransplantation From PERV‐C Free DPF Donor Piglets in Patients With Type 1 Diabetes},
  journal = {Xenotransplantation},
  year = {2026},
  volume = {33},
  number = {3},
  doi = {10.1111/xen.70148}
}
Kostenlos starten →